Navigation Links
Platinum Underwriters Holdings, Ltd. Reports Record Fourth Quarter and Year Ended December 31, 2007 Financial Results
Date:2/19/2008

$112,842

GAAP underwriting ratios:

Loss and LAE 35.7% 62.6% (70.7%) 48.1%

Acquisition expense 13.6% 24.4% 85.1% 21.2%

Other underwriting expense 7.5% 4.7% 10.2% 6.0%

Combined 56.8% 91.7% 24.6% 75.3%

Three Months Ended December 31, 2006

Segment underwriting results

Net premiums written $91,023 173,725 10,825 $275,573

Net premiums earned 106,637 191,173 17,916 315,726

Net losses and LAE 41,024 128,728 5,184 174,936

Net acquisition expenses 15,122 47,692 2,824 65,638

Other underwriting expenses 12,245 3,535 452 16,232

Total underwriting expenses 68,391 179,955 8,460 256,806

Segment underwriting income $38,246 11,218 9,456 58,920

Net investment income 50,822

Net realized gains on investments 1,068

Net foreign currency exchange gains 277

Other expense (945)

Corporate expenses not allocated to

segments (7,530)

Interest expense (5,453)

Income before income tax expense $97,159

GAAP underwriting ratios:

Loss and LAE 38.5% 67.3% 28.9% 55.4%

Acquisition expense 14.2% 24.9% 15.8% 20.8%

Other underwriting expense 11.5% 1.8% 2.5% 5.1%

Combined 64.2% 94.0% 47.2% 81.3%

The GAAP
'/>"/>

SOURCE Platinum Underwriters Holdings, Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Platinum Underwriters Holdings, Ltd. to Report Third Quarter 2007 Results on October 23, 2007
2. Disability Management Employer Coalition Names Mercer as Newest Platinum Sponsor
3. Mayo Clinic reports possible new therapy for patients with platinum-resistant ovarian cancer
4. IncentOne Receives Incentive Platinum Partner Award
5. Light powered platinum more targeted and 80 times more powerful than similar cancer treatments
6. Study reveals why certain ovarian cancers develop resistance to platinum-based chemotherapy
7. AMN Healthcare Services Acquires Platinum Select
8. Hooper Holmes to Exhibit at the 2007 Sixth Annual Association of Home Office Underwriters Conference
9. Pharmassets Underwriters Release Shares from Lock-Up
10. Darwin Professional Underwriters, Inc. Reports Record Net Income of $8.4 Million for the Third Quarter
11. Specialty Underwriters Alliance to Present at 2007 FBR Capital Markets Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...ospital Ship Serving in West Africa Receives Acces...ley, Texas October 6, 2008 -- www.seamobile.com [S... of communications services to remote locations, a...oxNews channel via satellite to Mercy Ships onboar... The Africa Mercy is the world,s largest non-gove...
(Date:10/5/2008)...iderable disparities in survival related to race a...and neck cancer. Published in the November 15, 200...e American Cancer Society, the study indicates tha...t could improve outcomes for these cancers among A...dies have examined disparities in cancer survival ...
(Date:10/5/2008)...ifficult to kill a spider as it scurries across th...er set foot on a plane. While nothing physically ...r can keep them from the task at hand. , The sam...hysical activity, according to research presented ... , Researchers from the Center for Obesity Resea...
(Date:10/3/2008)...ide Komen Community Challenge Campaign to Close,th...come Women and Women of ... Pennsylvania House Speaker Dennis,O,Brien (R-169t... survivors,and advocates from the Philadelphia Aff...ic forum this morning to call for policies to clos...
Breaking Medicine News(10 mins):Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3Health News:News from Cancer: Disparities in head and neck cancer patients 2Health News:Mental barriers hamper obese women's efforts to get exercise 2Health News:Susan G. Komen for the Cure(R), Speaker Dennis O'Brien, Obama and McCain Health Care Advisors, Breast Cancer Survivors and Advocates Call for Needed Health Care Reforms 2Health News:Susan G. Komen for the Cure(R), Speaker Dennis O'Brien, Obama and McCain Health Care Advisors, Breast Cancer Survivors and Advocates Call for Needed Health Care Reforms 3
...cably at an average age of 14, conventional autops...researchers conducted a// sophisticated form of po...utopsy -- they found that more than one-third died... defects that impair the heart’s rhythm center. T...
...leased by the Health Protection Agency (HPA) of Br... cases of infection by bugs including the potentia... the ‘super bug’ MRSA. According to the released ...tridium infections have risen drastically by 5.5 p...
...ncy Services (TCS) Tuesday announced a $6 million ...ay Hospitals to provide and implement a healthcare...e deal, TCS will work with Parkway Hospitals to cu...ement Solution (HMS) as per its specific needs, a ...
...umans to treat obesity from a drug derived from th...over, the Managing Director of the company. As pe...in Cannabis plant and each part of the plant has a... part of the cannabis plant has the power to curb ...
Other Medicine News:Health News:Young People Who Died Suddenly, Inexplicably Had Genetic Heart Defects 2Health News:Young People Who Died Suddenly, Inexplicably Had Genetic Heart Defects 3Health News:Lethal Hospital Bug Tough to Knock Down, Statistics Reveal 2
(Date:10/6/2008)...ntific Conference -, ORLANDO, Fla., Oct. 6 /PRNew...bia) today announced presentation of data from a p...at cyclic guanosine,monophosphate (cGMP) plays in ...rate that cGMP inhibits intestinal pain in a precl...itizes colonic afferent nerves in a,similar model ...
(Date:10/6/2008)...py is More Likely to Induce Steroid-Free Remissi... Immunomodulator, Azathioprine, OR... for the first time,from the Phase 3b Study of Pat...rs and Biologic Therapy (SONIC) may provide new in...moderate to severe Crohn,s disease.,According to f...
(Date:10/6/2008)...Naltrexone SR Associated with Bette.... 6 /- Orexigen Therapeutic...any focused on the treatment of,obesity and other ...esented,data showing the investigational drug, Con...lly achieved key objectives (lowered naltrexone,Cm...
(Date:10/5/2008)...f Medicine reaffirm,well-established efficacy and ...R), RIDGEFIELD, Conn., and NEW YORK, Oct. 5 /PRNe...tential Long-term Impacts on Function with,Tiotrop...tiotropium bromide,inhalation powder), sustained i...measured by FEV(1) (p<0.001) versus placebo in Chr...
Breaking Medicine Technology:Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 2Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 3Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 4Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 2Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 3Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 4Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 6Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 1Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 2Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 3Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 4Delivering Molecular Imaging Solutions Across Clinical Specialties 3A Siemens Showcases New Technologies at RSNA 2007 1871 5Regular exercise reduces risk of blood clots 6712 1Evolutionary comparison finds new human genes 1289 1Evolutionary comparison finds new human genes 1289 2Evolutionary comparison finds new human genes 1289 3New book presents methods to poke and prod individual molecules 1284 1New book presents methods to poke and prod individual molecules 1284 2
...ides Update to Timeline for Second Pivotal Phase 3...irstCall/ -- Advanced Life,Sciences Holdings, Inc....l efficacy data from Trial CL-06, the first of two...s the safety and,effectiveness of cethromycin, a n...ommunity acquired pneumonia (CAP). The Company,als...
...HINGTON, January 29, 2007 /PRNewswire-USNewswire/ ...), the President,s,Malaria Coordinator, announced ...Deputy Coordinator of the President,s Malaria,Init... in the U.S.,Public Heath Service and has most rec...luation, at the Global Fund to Fight,AIDS, Tubercu...
Other Medicine Technology:Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 2Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 3Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 4Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 5Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 6Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 7Studies of Drug Resistance May Lead to Individual Therapy for Rare,Cancers 2
...rt SI inserter from Bausch & Lomb provides fingert...ned for one handed delivery of the IOL directly in...assured by planar delivery. Leading haptic is posi...bag without sweeping motion. No additional instrum...
...erex Ultra Q is the fundamental capsulotmy laser -...ergy delivery and provides 2855% less energy in ai... in contemporary systems. This technology elimina...educes the risk of IOL pitting. , , , Ultr...
Protects the eye during or after surgery or trauma. Clear window dressing. Protects the eye allowing the patient to see.
Product designed specifically for posteror segment surgical procedures. For dissection of vitreoretinal membrames using viscoelastic fluid. A high pressure luer lock tubing set is attached to cannula
Medicine Products: